We cover the latest Imago Biosciences headlines and breaking news impacting Imago Biosciences stock performance. Investing.com - Financial Markets Worldwide Open in App ...

Merck & Co Inc said on Monday it will acquire cancer drug developer Imago BioSciences Inc for a total equity value of $1.35 billion to expand its portfolio of blood disorder treatments.

Shares of Imago BioSciences Inc. soared 104.9% into record territory in premarket trading Monday, after the biopharmaceutical company developing treatments for myeloproliferative neoplasms (MPNs ...

FTSE 100 Live: Stocks set to start 2024 on the front foot ...

Imago BioSciences, Inc. , a U.S. biotech developer of innovative treatments for bone marrow cancer patients, will become part of the Merck & Co., Inc. family under a recently announced agreement.

Imago BioSciences is a clinical-stage biopharmaceutical company discovering and developing novel small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that ...

The West Coast company being acquired is developing treatments for a variety of bone marrow disorders. North Jersey Big Pharma company Merck, which has a large presence in Montgomery County, has ...

Imago BioSciences (NASDAQ:IMGO) has observed the following analyst ratings within the last quarter: In the last 3 months, 5 analysts have offered 12-month price targets for Imago BioSciences. The ...

Merck & Co. has agreed to buy blood-cancer biotech Imago BioSciences Inc. for $1.35 billion, the big drugmaker’s latest deal in search of new sources of sales. Under the terms, Merck said Monday ...

Merck & Co (Merck) – known as MSD outside the US and Canada – has announced it will acquire Imago BioSciences (Imago) in a deal worth $1.35bn. Under the terms of the agreement, Merck, through a ...

Read the latest Imago Biosciences Inc share news, written by our expert team of financial journalists. Don't miss today's top IMGO stories.

Within the last quarter, Imago BioSciences (NASDAQ:IMGO) has observed the following analyst ratings: According to 6 analyst offering 12-month price targets in the last 3 months, Imago BioSciences ...